Psilocybin in the Treatment of Cocaine Use Disorder: A Randomized Clinical Trial

By
Peter S. Hendricks
Sara N. Lappan
Richard C. Shelton
Adrienne C. Lahti
Karen L. Cropsey
Matthew W. Johnson
Melissa Bradley
Otto Simonsson
Lori L. Davis
Daniel H. Grossman
Cynthia E. Ortiz
May 7, 2026
0 min

Jama Network Open

Overview

This randomized clinical study investigates the efficacy of psilocybin in treating cocaine use disorder (CUD). Results indicate that participants receiving psilocybin showed a higher percentage of cocaine-abstinent days and a greater likelihood of complete abstinence compared to those receiving an active placebo.

Background

Cocaine use disorder presents significant public health challenges, with rising global usage and limited effective pharmacotherapies. Current treatments primarily focus on behavioral interventions, such as contingency management, which have shown some success in improving abstinence rates. The exploration of psilocybin as a potential therapeutic option represents a novel approach in addressing this pressing issue.

Data Highlights

Revise to reflect relevant findings from the study instead of stating no numerical data.

Key Findings

Incorporate specific percentages or numerical data to support claims about abstinence rates and latency to lapse.

Clinical Implications

The findings suggest that psilocybin, when combined with psychotherapy, may offer a promising new avenue for treating cocaine use disorder. Clinicians should consider the potential of psychedelics in their treatment protocols, particularly for patients who have not responded to traditional therapies.

Conclusion

This study provides preliminary evidence supporting the use of psilocybin as a therapeutic option for cocaine use disorder. Further research is needed to confirm these findings and explore the underlying mechanisms of action.